More on IDYA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-21.6% Growth)
- Ratings (9.2 Score)

Upcoming Events

- Earnings (8/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

IDEAYA Biosciences (NQ:IDYA)
Delayed: 31.23 -0.03 (0.1%)
Prev. Close $31.26  
Open$31.84 
52 Wk High$ 
52 Wk Low$ 
Day High$32.34 
Day Low$30.65 
P/E N/A  
EPS$ 
Volume2,018,518 

Friends, Peers and Foes (?): CATX, SMMT, EXAS, ILMN, IR (more...)

Jun 18, 2026 04:34 PM Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: YARNO WENDY L
Jun 18, 2026 04:34 PM Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Stein Jeffrey
Jun 18, 2026 04:33 PM Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: ROSEN TERRY J
Jun 18, 2026 04:33 PM Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Morrison Scott W
Jun 18, 2026 04:32 PM Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: MACKEY CATHERINE J
Jun 18, 2026 04:31 PM Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Hampton Malcolm Garret
Jun 17, 2026 06:01 AM IDEAYA Biosciences names CEO Yujiro Hata as board chairman
Jun 17, 2026 06:00 AM IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
Jun 15, 2026 06:00 AM IDEAYA starts phase 1/2 trial of IDE892 for pancreatic, lung cancers
Jun 15, 2026 06:00 AM IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
View All Articles

Entities mentioned with IDYA

View All Entities